Physician profile
Patrick D Chan-Lam
NPI 1205807575
$4,187.92
in general payments reported to CMS, 2019-2025
32 companies · $889 in 2025
The $889 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,309 · 2020: $238 · 2021: $601 · 2022: $523 · 2023: $357 · 2024: $270 · 2025: $889.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $887 · Travel and Lodging: $629.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $886.79 |
| Travel and Lodging | $629.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $629.40 | 2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Amgen INC. | $533.60 | 2019-2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $328.16 | 2019-2025 | Lifevest |
| Boehringer Ingelheim Pharmaceuticals, INC. | $318.19 | 2019-2024 | Jardiance |
| Pfizer INC. | $282.52 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $272.75 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $188.27 | 2019-2025 | Camzyos, Eliquis |
| Janssen Pharmaceuticals, INC | $185.54 | 2019-2022 | |
| Biotronik INC. | $179.93 | 2019-2022 | |
| Medtronic Vascular, INC. | $123.82 | 2019 | |
| Amarin Pharma, INC. | $111.47 | 2019-2022 | |
| Astellas Pharma US INC | $110.27 | 2019-2021 | |
| Akcea Therapeutics, INC. | $108.71 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $99.00 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $90.93 | 2021-2023 | Verquvo |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $78.57 | 2023-2024 | Watchman Flx |
| Kiniksa Pharmaceuticals International, Plc | $73.02 | 2024 | Arcalyst |
| Impulse Dynamics (USA) INC. | $60.56 | 2023 | Optimizer |
| Scpharmaceuticals INC. | $54.51 | 2023-2025 | |
| Cardiofocus, INC. | $53.60 | 2019 | |
| Sanofi-Aventis U.S. LLC | $46.93 | 2019-2023 | |
| Esperion Therapeutics, INC. | $40.40 | 2021 | |
| Lexicon Pharmaceuticals, INC. | $39.14 | 2023-2024 | Inpefa |
| Astrazeneca Pharmaceuticals Lp | $29.37 | 2021-2025 | Farxiga |
| Baxter Healthcare | $24.70 | 2022 | |
| Gilead Sciences, INC. | $23.20 | 2019 | |
| Irhythm Technologies, INC. | $22.29 | 2024 | Zio Xt Patch, Zio Monitor |
| Glaxosmithkline, LLC. | $20.17 | 2025 | Shingrix, Arexvy |
| Abbott Laboratories | $17.61 | 2019 | |
| Kiniksa Pharmaceuticals, Ltd. | $15.06 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $14.36 | 2021 | |
| Philips North America LLC | $11.87 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Chan-Lam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.